image credit: Vecteezy

Cancer Research UK to support Aleta in bringing CAR-T cell therapy through clinical trials

June 23, 2021

Cancer Research UK will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of Aleta’s CAR-T cell engager candidate, ALETA-001.

ALETA-001 is part of Aleta’s pipeline of therapies targeting blood cancers and solid tumours. It is being developed to treat people with B-cell lymphoma and leukaemia whose disease has progressed after receiving CD19 CAR-T cell therapy. If brought to market, ALETA-001 could offer another therapy for patients with limited treatment options.

Read More on EPM Magazine